Genetics and epigenetics of liver cancer.

[1]  I. Rusyn,et al.  Role of epigenetic aberrations in the development and progression of human hepatocellular carcinoma. , 2014, Cancer letters.

[2]  Boping Zhou,et al.  Exome sequencing of hepatitis B virus–associated hepatocellular carcinoma , 2012, Nature Genetics.

[3]  Chun-Ming Wong,et al.  Enhancer of zeste homolog 2 epigenetically silences multiple tumor suppressor microRNAs to promote liver cancer metastasis , 2012, Hepatology.

[4]  V. Mazzaferro,et al.  Wnt-Pathway Activation in Two Molecular Classes of Hepatocellular Carcinoma and Experimental Modulation by Sorafenib , 2012, Clinical Cancer Research.

[5]  Keith A. Boroevich,et al.  Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators , 2012, Nature Genetics.

[6]  S. Imbeaud,et al.  Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma , 2012, Nature Genetics.

[7]  H. El‐Serag,et al.  Epidemiology of viral hepatitis and hepatocellular carcinoma. , 2012, Gastroenterology.

[8]  J. Eun,et al.  HDAC1 Inactivation Induces Mitotic Defect and Caspase-Independent Autophagic Cell Death in Liver Cancer , 2012, PloS one.

[9]  V. Mazzaferro,et al.  Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib. , 2012, Clinical cancer research : an official journal of the American Association for Cancer Research.

[10]  M. Esteller,et al.  Cancer epigenomics: beyond genomics. , 2012, Current opinion in genetics & development.

[11]  Fang Wang,et al.  The histone deacetylase 4/SP1/microrna‐200a regulatory network contributes to aberrant histone acetylation in hepatocellular carcinoma , 2011, Hepatology.

[12]  Shuhan Sun,et al.  Long noncoding RNA high expression in hepatocellular carcinoma facilitates tumor growth through enhancer of zeste homolog 2 in humans , 2011, Hepatology.

[13]  H. Sitter,et al.  Clinical significance of histone deacetylases 1, 2, 3, and 7: HDAC2 is an independent predictor of survival in HCC , 2011, Virchows Archiv.

[14]  Jun Yu,et al.  EZH2-mediated concordant repression of Wnt antagonists promotes β-catenin-dependent hepatocarcinogenesis. , 2011, Cancer research.

[15]  C. Wray,et al.  Clinical implications of DNA methylation in hepatocellular carcinoma. , 2011, HPB : the official journal of the International Hepato Pancreato Biliary Association.

[16]  Yongmei Li,et al.  ShRNA-Targeted Centromere Protein A Inhibits Hepatocellular Carcinoma Growth , 2011, PloS one.

[17]  M. Esteller,et al.  Cancer epigenetics reaches mainstream oncology , 2011, Nature Medicine.

[18]  Y. Zeng,et al.  EZH2 protein: a promising immunomarker for the detection of hepatocellular carcinomas in liver needle biopsies , 2011, Gut.

[19]  Haiyang Xie,et al.  Identification of Histone Deacetylase 3 as a Biomarker for Tumor Recurrence Following Liver Transplantation in HBV-Associated Hepatocellular Carcinoma , 2010, PloS one.

[20]  Angela M. Liu,et al.  microRNA-122 as a regulator of mitochondrial metabolic gene network in hepatocellular carcinoma , 2010, Molecular systems biology.

[21]  M. Sakamoto,et al.  Bmi‐1 gene is upregulated in early‐stage hepatocellular carcinoma and correlates with ATP‐binding cassette transporter B1 expression , 2010, Cancer science.

[22]  M. Ozturk,et al.  Senescence and immortality in hepatocellular carcinoma. , 2009, Cancer letters.

[23]  W. Weichert.  HDAC expression and clinical prognosis in human malignancies. , 2009, Cancer letters.

[24]  Y. Nakanuma,et al.  The overexpression of polycomb group proteins Bmi1 and EZH2 is associated with the progression and aggressive biological behavior of hepatocellular carcinoma , 2008, Laboratory Investigation.

[25]  J. Marrero,et al.  Diagnosis and treatment of hepatocellular carcinoma. , 2008, Gastroenterology.

[26]  T. Okanoue,et al.  Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues , 2006, Oncogene.

[27]  M. Buendia.  Genetic alterations in hepatoblastoma and hepatocellular carcinoma: common and distinctive aspects. , 2002, Medical and pediatric oncology.

[28]  Hengbin Wang,et al.  Role of Histone H3 Lysine 27 Methylation in Polycomb-Group Silencing , 2002, Science.

[29]  H Ishii,et al.  Expression of mRNA for DNA methyltransferases and methyl‐CpG–binding proteins and DNA methylation status on CpG islands and pericentromeric satellite regions during human hepatocarcinogenesis , 2001, Hepatology.

[30]  C. Bréchot,et al.  Molecular bases for the development of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC). , 2000, Seminars in cancer biology.

[31]  K. Isselbacher,et al.  Abnormal structure and expression of p53 gene in human hepatocellular carcinoma. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[32]  Christine Pourcel,et al.  Presence of integrated hepatitis B virus DNA sequences in cellular DNA of human hepatocellular carcinoma , 1980, Nature.

[33]  E. Yu,et al.  Expression of DNA methyltransferases in multistep hepatocarcinogenesis. , 2003, Human pathology.

[34]  M. Ozturk.  Genetic Aspects of Hepatocellular Carcinogenesis , 1999, Seminars in liver disease.

[35]  D. Woodfield.  Hepatocellular carcinoma. , 1986, The New Zealand medical journal.